Alyeska Investment Group’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-538,579
| Closed | -$3.15M | – | 576 |
|
|
2022
Q4 | $3.15M | Buy |
538,579
+38,579
| +8% | +$203K | 0.03% | 290 |
|
|
2022
Q3 | $3.35M | Sell |
500,000
-100,000
| -17% | -$606K | 0.04% | 290 |
|
|
2022
Q2 | $2.53M | Buy |
600,000
+51,910
| +9% | +$205K | 0.03% | 375 |
|
|
2022
Q1 | $1.85M | Hold |
548,090
| – | – | 0.02% | 441 |
|
|
2021
Q4 | $1.73M | Buy |
548,090
+50,000
| +10% | +$166K | 0.02% | 463 |
|
|
2021
Q3 | $1.63M | Hold |
498,090
| – | – | 0.02% | 528 |
|
|
2021
Q2 | $2.1M | Buy |
498,090
+150,871
| +43% | +$639K | 0.02% | 503 |
|
|
2021
Q1 | $1.73M | Hold |
347,219
| – | – | 0.02% | 492 |
|
|
2020
Q4 | $4.39M | Sell |
347,219
-193,135
| -36% | -$2.2M | 0.06% | 297 |
|
|
2020
Q3 | $5.31M | Buy |
540,354
+37,571
| +7% | +$370K | 0.08% | 254 |
|
|
2020
Q2 | $5M | Buy |
502,783
+50,883
| +11% | +$488K | 0.08% | 268 |
|
|
2020
Q1 | $4M | Buy |
451,900
+133,262
| +42% | +$1.31M | 0.08% | 213 |
|
|
2019
Q4 | $2.94M | Buy |
+318,638
| New | +$2.26M | 0.04% | 266 |
|
|
2019
Q3 | – | Sell |
-307,738
| Closed | -$3.69M | – | 531 |
|
|
2019
Q2 | $3.69M | Buy |
307,738
+93,369
| +44% | +$1M | 0.05% | 266 |
|
|
2019
Q1 | $2.59M | Buy |
214,369
+119,369
| +126% | +$1.76M | 0.03% | 266 |
|
|
2018
Q4 | $1.19M | Buy |
+95,000
| New | +$1.31M | 0.02% | 313 |
|
|
2017
Q4 | – | Sell |
-368,243
| Closed | -$5.43M | – | 553 |
|
|
2017
Q3 | $5.43M | Buy |
368,243
+6,576
| +2% | +$95.4K | 0.04% | 287 |
|
|
2017
Q2 | $5.04M | Buy |
361,667
+159,595
| +79% | +$2.35M | 0.04% | 284 |
|
|
2017
Q1 | $3.45M | Sell |
202,072
-154,143
| -43% | -$1.85M | 0.03% | 352 |
|
|
2016
Q4 | $3.67M | Buy |
356,215
+25,378
| +8% | +$232K | 0.03% | 352 |
|
|
2016
Q3 | $3.35M | Buy |
+330,837
| New | +$3.61M | 0.03% | 355 |
|
|
2015
Q4 | – | Sell |
-162,534
| Closed | -$3.05M | – | 484 |
|
|
2015
Q3 | $3.05M | Buy |
162,534
+27,273
| +20% | +$464K | 0.04% | 300 |
|
|
2015
Q2 | $2.01M | Buy |
135,261
+5,261
| +4% | +$80.1K | 0.02% | 351 |
|
|
2015
Q1 | $1.97M | Buy |
+130,000
| New | +$1.81M | 0.03% | 372 |
|
|
2014
Q4 | – | Sell |
-102,280
| Closed | -$1.29M | – | 543 |
|
|
2014
Q3 | $1.29M | Sell |
102,280
-51,967
| -34% | -$504K | 0.03% | 312 |
|
|
2014
Q2 | $1.56M | Sell |
154,247
-138,526
| -47% | -$1.34M | 0.03% | 329 |
|
|
2014
Q1 | $3.94M | Buy |
+292,773
| New | +$4.13M | 0.11% | 219 |
|
Alyeska Investment Group's CNCE Position: Q1 2023 in Review
Alyeska Investment Group sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 538,579 shares — an estimated $3.15M sold.
Alyeska Investment Group first reported a position in CNCE in Q1 2014 and held it in 27 quarters. The position peaked at $5.43M in Q3 2017. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Alyeska Investment Group reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Alyeska Investment Group sold 538,579 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $3.15M.
- Alyeska Investment Group first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 27 quarters.
- Alyeska Investment Group's Concert Pharmaceuticals, Inc. position peaked at $5.43M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Alyeska Investment Group's 13F filing for Q1 2023, filed 15 May 2023.